Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
Pfizer Inc. reports developments across its global biopharmaceutical business, including prescription medicines, vaccines, biosimilars, sterile injectables, and oncology therapies. Recurring news covers financial results and guidance, commercial portfolio changes within Biopharma, dividend declarations, capital allocation priorities, and product access initiatives for established medicines such as Eliquis.
Company updates also address clinical and regulatory activity across Pfizer's pipeline and marketed products. Recent themes include oncology data presentations, Phase 3 results for ELREXFIO in relapsed or refractory multiple myeloma, PADCEV combination regulatory activity in bladder cancer, VYNDAMAX patent litigation settlements, and shareholder meeting communications.
Pfizer Inc. (NYSE: PFE) announced positive top-line results from the Phase 2b/3 ALLEGRO trial for ritlecitinib, an oral treatment for alopecia areata. The study met its primary endpoint, showing significant scalp hair regrowth in patients with at least 50% hair loss. Ritlecitinib’s safety profile was consistent with earlier studies, with common adverse events including nasopharyngitis and headache. There were no major adverse cardiac events reported. Full study results will be published, supporting future regulatory filings.
Pfizer Inc. (NYSE: PFE) reported a substantial 92% revenue increase in Q2 2021, totaling $18.98 billion, attributed to strong sales of its COVID-19 vaccine, BNT162b2, which alone contributed $7.8 billion. The company raised its 2021 financial guidance, now expecting revenues of $78.0 to $80.0 billion. Adjusted diluted EPS is projected between $3.95 and $4.05, reflecting a 77% increase from 2020. The company also reported a 10% operational growth in its business excluding the vaccine. Pfizer aims for a 6% CAGR through 2025, buoyed by promising clinical pipelines and revenue forecasts.
Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) announced the U.S. government's purchase of an additional 200 million doses of their COVID-19 vaccine. This increases the total to 500 million doses under their supply agreement. The companies plan to deliver 110 million doses by December 31, 2021, and the remaining doses by April 30, 2022. The U.S. government will continue to provide the vaccine for free. The vaccine remains under Emergency Use Authorization and is aimed at preventing COVID-19.
Pfizer (NYSE: PFE) announced the FDA will not meet the PDUFA goal dates for its New Drug Application for abrocitinib, aimed at treating moderate to severe atopic dermatitis, and the supplemental application for XELJANZ/XELJANZ XR (tofacitinib) for active ankylosing spondylitis. The delay is attributed to the FDA's ongoing review of Pfizer's post-marketing safety study for tofacitinib in rheumatoid arthritis. Pfizer remains confident in the benefit-risk profiles of both drugs.
Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) have signed a letter of intent with The Biovac Institute to manufacture and distribute the Pfizer-BioNTech COVID-19 Vaccine in Africa. Biovac will join Pfizer's global supply chain, enhancing production capabilities across three continents with over 20 facilities. Production is set to begin in 2022, aiming for more than 100 million doses annually for the African Union. This collaboration underscores Pfizer's commitment to equitable vaccine access and explores further partnerships in Latin America.
Pfizer Inc. (NYSE: PFE) announces the appointment of Christopher Stevo as Senior Vice President and Chief Investor Relations Officer. He succeeds Chuck Triano, who is retiring after 13 years. Stevo brings over two decades of buy-side healthcare investment experience, previously serving at Alexion Pharmaceuticals and Amundi US. Pfizer's CEO, Albert Bourla, highlighted Stevo's extensive knowledge of the healthcare sector as a significant asset for the company's innovative pipeline aimed at delivering value to shareholders.
Everest Medicines announced a licensing agreement between its partner Spero Therapeutics and Pfizer for SPR206, a new treatment for multi-drug resistant Gram-negative infections. Under this deal, Spero will receive up to $80 million in milestone payments and royalties on sales, alongside a $40 million equity investment from Pfizer. This partnership enhances the clinical development of SPR206 while maintaining Everest's exclusive rights in Greater China, South Korea, and certain Southeast Asian countries.
Pfizer Inc. (NYSE: PFE) announced a 39-cent quarterly dividend for Q3 2021, payable on September 7, 2021, to stockholders recorded by July 30, 2021. This marks the 331st consecutive quarterly dividend from Pfizer, showcasing its commitment to returning value to shareholders. The company emphasizes its role in delivering innovative health care solutions and maintaining high standards in the biopharmaceutical industry.
Pfizer Inc. (NYSE: PFE) announced the initiation of the TALAPRO-3 trial, a global Phase 3 study investigating the efficacy and safety of talazoparib combined with enzalutamide in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer. The trial will enroll approximately 550 participants across 285 sites in 28 countries, with a primary endpoint of radiographic progression-free survival (rPFS). The first patient was dosed in Glendale, California, and results are anticipated in late 2024.
ViiV Healthcare and Halozyme Therapeutics have entered a global collaboration that grants ViiV exclusive access to Halozyme's ENHANZE® drug delivery technology for HIV treatments. ViiV will pay $40 million upfront, with potential milestone payments totaling up to $175 million per target. This partnership aims to enhance the development of long-acting HIV therapies, reducing the frequency of medication. The PH20 enzyme allows for efficient large-volume subcutaneous injections, potentially addressing treatment challenges for patients and improving their experience.